Skip to content

Stock·NYSE·Healthcare

AbbVie Inc. (ABBV)

$286.20 +2.66 (+0.94%)
At close: Nov 20, 4:00 PM EST
Buy
66 / 100
CleaRank Financial AI scorei
Market cap
$505.89B
P/E
49.18
Dividend yield
2.42%
Street target
$317.00median of 29 analysts
52-week range
$190.75 $302.93

What moved AbbVie Inc. (ABBV)

Market figures as of November 20, 2026.

Was it the market or the company?

On November 20, 2026, ABBV rose 0.94%. The same day the S&P 500 (SPY) fell 3.64%, the Nasdaq 100 (QQQ) fell 5.67% and the health care sector (XLV) fell 0.12%.

The move was in line with the market. ABBV's one-year beta to SPY is -0.01, so SPY's -3.64% would on average have meant +0.03% for ABBV, close to what it did (0.9 percentage points more).

Over the last 20 sessions ABBV is up 0.20% against -9.23% for SPY, 9.4 percentage points ahead of it.

The wider market on November 20, 2026: CNBC reported that the sell-off's breaking point came with Anthropic's initial public offering and heavier selling in Nvidia, which it named as the first of five forces behind the drop. (CNBC, November 20, 2026)

Moves to November 20, 2026, side by side
That day 5 sessions 20 sessions
ABBV +0.94% -2.99% +0.20%
S&P 500 (SPY) -3.64% -8.56% -9.23%
Nasdaq 100 (QQQ) -5.67% -10.51% -13.62%
Health care sector (XLV) -0.12% -6.15% -1.14%

Calculated by CleaRank from daily closes. Beta is measured on the last year of daily returns against SPY. A description of what happened, not a forecast.

01

ABBV stock today, November 22, 2026: price, news and analyst targets

As of November 20, 2026, AbbVie Inc. (ABBV) trades at $286.20. Wall Street's median 12-month price target is $317.00 across 29 analysts, 10.8% above the price. CleaRank rates it Buy with a score of 66/100.

AbbVie shares sit at $286.20, about 5.85% above their 52-week high of $302.93 and above its 50-day and 200-day moving averages ($279.00 and $242.45), while the 20-day exponential average at $288.54 is the first hurdle overhead. The stock slipped 2.99% over the past week after a November 18, 2026 decline of 2.33% that closed at $286.01, so the recent pullback has come from a close near its 52-week peak. Analysts remain constructive, with 23 of 29 rating the stock buy or strong buy, but the valuation is stretched, with a trailing P/E of 49.18 against a sector median of 31.9. That combination of strong trend and rich valuation frames the next few weeks.

Why the trend still favours the stock

AbbVie trades 2.58% above its 50-day simple average and 18.04% above its 200-day average, with the 50-day average itself 15.08% above the 200-day. That alignment of averages is the core of the CleaRank trend reading, which is strongly positive. Over the past year the stock has risen 24.73%, and over six months 32.68%, so the advance has been sustained rather than a single spike. The price has also been close to its high: the November 13, 2026 close of $295.03 was its highest in 52 weeks.

What the recent pullback means

The shares are down 2.99% over the past week and fell 2.33% on November 18, 2026, closing at $286.01. The move was larger than the stock's typical daily swing of 1.43%, though the 30-day standard deviation is a backward-looking measure. The stock also fell 2.05% in the first session after the October 30, 2026 report, despite the EPS beat. Three of the four most recent earnings reports were followed by a lower first-session price, so investors have sold into good numbers before. Against this, the 20-day average is still the first ceiling, and the MACD line is positive, which suggests the momentum behind the trend has not yet turned.

Valuation is the main drag

At a trailing P/E of 49.18, AbbVie trades at a premium to peers, 54.2% above the sector median of 31.9. The price-to-sales ratio of 7.73 is 127.2% above the sector median of 3.4. Trailing GAAP earnings of $5.82 per share underpin that multiple, and analysts expect this fiscal year's EPS to reach $13.98 on their adjusted basis, a 39.8% rise. Revenue grew 10.16% in the latest quarter year on year, faster than the sector median of 8.1% by 2.1 percentage points, and the operating margin of 36.64% is high. The business is growing faster than its peers, but the price already reflects a great deal of that growth.

Insider selling and analyst support

Insiders sold $41.9M of stock over the last 18 months across seven sales, with no open-market purchases. Such sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than buying. On the analyst side, 23 of 29 ratings are buy or strong buy, 5 are hold and 1 is sell, and the median 12-month target is $317.00, 10.8% above the price. Three months ago 25 of 31 ratings were buy, so the share of buy ratings has risen slightly.

CleaRank score 66/100 (Buy). 15 of 19 checks pass: trend 4 of 4, momentum 2 of 3, valuation and quality 3 of 5, analysts 2 of 3, track record 4 of 4.

About AbbVie

AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients with chronic autoimmune conditions, blood cancers, inflammatory disorders, and other specialized medical needs. The company’s portfolio includes branded prescription medicines and advanced therapies distributed through physicians, wholesalers, specialty pharmacies, healthcare facilities, and other healthcare channels.

02

ABBV stock news

  • Earnings beat

    Earnings report, October 30, 2026

    The October 30, 2026 report beat the EPS estimate by 1.60%, and the share price fell 2.05% in the first session after it.

  • Rating reaffirmed

    Analyst action, UBS, November 2, 2026

    UBS kept its Neutral rating on November 2, 2026.

03

ABBV price target 2026

The base case is that AbbVie holds above its 50-day average at $279.00 and works back toward the 20-day average and then the 52-week high, provided revenue keeps growing near the 10.16% pace of the latest quarter and margins stay high. The analysts' median 12-month target of $317.00 implies room to run if the company keeps meeting estimates, which it has done in each of its last four reports. The bullish case strengthens on a close above the November 13, 2026 high of $295.03 and a move through the $302.93 52-week high. The bearish case rests on the valuation: a loss of the 50-day average would bring the 200-day average at $242.45 into view, and slower growth against a P/E of 49.18 would make a premium that is hard to sustain. Analysts' estimates call for EPS growth of 39.8% this fiscal year and 15.8% next year, so the earnings path matters more than the price action in the short term.

Analyst targets and ratings

12-month price targets

Low $237.00 Median $317.00 (+10.8%) High $350.00

Ratings

Buy 23 Hold 5 Sell 1 3 months ago: 25 of 31 buy

Recent rating actions

Recent analyst rating actions on ABBV
Date Firm Action Rating
Nov 2, 2026 UBS Maintains Neutral
Nov 2, 2026 Leerink Partners Maintains Outperform
Nov 2, 2026 Morgan Stanley Maintains Overweight
Nov 2, 2026 Guggenheim Maintains Buy
Nov 2, 2026 Wells Fargo Maintains Overweight
Nov 2, 2026 RBC Capital Maintains Outperform
04

ABBV support and resistance levels

Support sits at $279.00, the 50-day simple moving average, the nearest level below the price; a close beneath it would signal the uptrend losing its footing. The next support is the 200-day simple moving average at $242.45, which the stock has held comfortably for months. The third support is the 52-week low of $190.75. Resistance starts at the 20-day exponential moving average at $288.54, a level the price sits just under and that has to be reclaimed for short-term momentum to improve.

ABBV support and resistance levels
Level What it is Price From the price
Resistance 2 52-week high $302.93 +5.8%
Resistance 1 20-day exponential average $288.54 +0.8%
Price November 20, 2026 $286.20
Support 1 50-day moving average $279.00 -2.5%
Support 2 200-day moving average $242.45 -15.3%
Support 3 52-week low $190.75 -33.4%

Technical indicators

Technical rating Bullish 3 of 4 signals bullish
  • RSI Neutral
  • SMA cross Bullish
  • Price vs SMA Bullish
  • MACD Bullish
Momentum Neutral
49.214-day RSI
Oversold <30 Neutral Overbought >70
MACD (12, 26) 2.48 Bullish
Trend Golden cross
+2.6%price against the 50-day average
200-day $242.45 50-day $279.00 Price $286.20
Price against the 200-day +18.0% Bullish

ABBV technical analysis in depth

Volatility, momentum, trend strength and the price levels that matter for ABBV, calculated by CleaRank from daily bars to November 20, 2026.

Volatility

On the 20-day Bollinger Bands (2 standard deviations) the bands run from $282.66 to $298.22 around a middle of $290.44, and ABBV's close of $286.20 sits inside the bands, away from both edges.

The bands are narrower than on 94% of the last 120 sessions: a squeeze, the kind of quiet stretch that has often come before a larger move in either direction.

The 14-day average true range is $6.703, or 2.3% of the price: a typical day's swing from high to low. A stop placed 1.5 ATR away would sit about 3.5% from the close.

Momentum and volume

The 14-day stochastic reads 27 (signal line 22): the close is in the middle of its two-week range.

The MACD line (12, 26) is 2.48 against a signal line (9) of 4.22, so the histogram is negative: momentum is weakening relative to its recent average. The MACD line crossed below its signal line 13 sessions ago.

Volume in the latest session was 1.7 times its 20-day average, heavy enough to give the move more weight.

Trend strength

The 14-day ADX is 25: a trending market, with buyers in control (+DI 28, -DI 24).

On the weekly chart the 10-week average ($280.61) is above the 40-week average ($243.28), a rising longer-term trend, and the weekly RSI is 65.

Key levels

The nearest resistance from the price history is $291.40 (+1.8%): a swing high set on October 15, 2026.

The nearest support is $279.54 (-2.3%): the price turned here 2 times, most recently on November 6, 2026.

The largest swing of the last 120 sessions ran up from $213.73 (June 3, 2026) to $302.93 (November 5, 2026); the nearest Fibonacci retracement to the price is the 23.6% level at $281.88.

Classic pivot points for the next session, from November 20, 2026: pivot $287.09, resistance $289.34 and $292.47, support $283.96 and $281.71.

ABBV key price levels
Level Price From the price What it is
Resistance (swing high) $302.93 +5.8% a swing high set on November 5, 2026
Upper Bollinger Band $298.22 +4.2% 20-day average + 2 standard deviations
Pivot R2 (classic) $292.47 +2.2% next-session level
Resistance (swing high) $291.40 +1.8% a swing high set on October 15, 2026
Pivot R1 (classic) $289.34 +1.1% next-session level
Pivot R1 (Fibonacci) $289.15 +1.0% 38.2% of the last range above the pivot
Pivot point $287.09 +0.3% average of the last high, low and close
Price $286.20 close, November 20, 2026
Pivot S1 (Fibonacci) $285.04 -0.4% 38.2% of the last range below the pivot
Pivot S1 (classic) $283.96 -0.8% next-session level
Lower Bollinger Band $282.66 -1.2% 20-day average - 2 standard deviations
Fibonacci 23.6% $281.88 -1.5% retracement of the rise from $213.73 to $302.93
Pivot S2 (classic) $281.71 -1.6% next-session level
Support (swing low) $279.54 -2.3% the price turned here 2 times, most recently on November 6, 2026
Fibonacci 38.2% $268.86 -6.1% retracement of the rise from $213.73 to $302.93
Support (swing low) $267.94 -6.4% the price turned here 3 times, most recently on September 23, 2026
Support (swing low) $261.18 -8.7% the price turned here 4 times, most recently on October 2, 2026
Fibonacci 50.0% $258.33 -9.7% retracement of the rise from $213.73 to $302.93
Fibonacci 61.8% $247.80 -13.4% retracement of the rise from $213.73 to $302.93
Fibonacci 78.6% $232.82 -18.7% retracement of the rise from $213.73 to $302.93

Swing levels are highs and lows the price turned at (the extreme of the five sessions either side), merged when they sit within 1.2 average true ranges of each other. Bollinger Bands (20, 2), ATR (14, Wilder), stochastic (14, 3), MACD (12, 26, 9), ADX (14, Wilder). Readings describe the chart; they are not a forecast.

05

ABBV stock price and trading

ABBV share price

Start $229.45 Nov 20, 2025
Latest close $286.20 Nov 20, 2026
High $295.03 Nov 13, 2026
Low $197.38 Apr 27, 2026
06

ABBV fundamentals and valuation

Key statistics

Market Cap
505.89B
P/E Ratio
49.18
EPS (TTM)
$5.82
Dividend Yield
2.42%
52 Week High
302.93
52 Week Low
190.75

ABBV against the Healthcare sector

P/E ratio 54% above the median
ABBV
49.2x
Sector median
31.9x
P/S ratio 127% above the median
ABBV
7.7x
Sector median
3.4x
Revenue growth, year on year 2.1 points above the median
ABBV
10.2%
Sector median
8.1%

Price to earnings vs sector: ABBV trades at a significant premium to sector peers (+54% against the sector median P/E). Investors are paying more for each dollar of earnings than for the typical stock in the sector.

Return vs XLV: Since Jun 11, 2025, ABBV has gained 49.5% against a gain of 30.6% for XLV.

Performance against XLV

ABBV XLV

Revenue and earnings

Revenue, 12 months
$66.0B
Net income, 12 months
$10.3B
Net margin
15.6%
Revenue growth
+10.2%
Q2 '26, year on year
FY202121% marginFY202220% marginFY20239% marginFY20248% marginFY20257% margin
Revenue Net income

Revenue growth: Revenue grew 8.6% in FY2025 to $61.2B, from $56.3B a year earlier.

Profit margin: The net margin was 6.9% in FY2025, down from 7.6% the year before.

Profitable: ABBV earned $4.2B in FY2025.

Earnings reality check

Beat the estimate
4 of 4
4 reports in our data
Fell after a beat
3 of 4
first session after the report
Average surprise
+2.4%
actual EPS against the estimate
Avg. first-session move
-1.6%
the stock, after the report
EPS surprise
First-session move
Oct '25Feb '26Jul '26Oct '26

Earnings record: ABBV beat the analyst estimate in 4 of the 4 reports in our data.

Market reaction: The stock fell in the first session after 3 of those 4 beats, so a beat has not been enough on its own.

ABBV earnings surprises and the stock's reaction
Report Estimate Actual Surprise First session 5 sessions
Oct 30, 2026 $3.76 $3.82 +1.60% -2.05% -1.21%
Jul 31, 2026 $3.61 $3.65 +1.11% -2.33% -1.95%
Feb 4, 2026 $2.65 $2.71 +2.26% +0.88% +1.74%
Oct 31, 2025 $1.78 $1.86 +4.49% -2.79% +0.51%
07

ABBV price history and drawdowns

Risk profile

Beta
0.19
against the S&P 500; 1 moves with the market
Daily volatility
1.43%
30-day standard deviation
52-week range
$286.20
$190.75 85% of the way up $302.93

Worst falls and recoveries

Worst fall, last 10 years
-43.5%
January 2018 to August 2019
Recovery
17 months
back at the old peak by January 2021
From the 10-year high
-3.0%
peak with dividends reinvested, November 2026
1-year holds that gained
84%
of every 1-year window

Growth of $10,000

ABBV today
$72,285
from $10,000 in December 2016, dividends reinvested
S&P 500 today
$36,764
the same $10,000 in SPY, dividends reinvested
Ahead of the index by
$35,522
2.0x the index result
Total change
+623%
7.2x the starting amount
ABBV S&P 500 (SPY)

Against the market: ABBV beat the S&P 500 over this period: $72,285 against $36,764.

A $10,000 investment in ABBV in December 2016 would be worth about $72,285 today with dividends reinvested, compared with about $36,764 for the same investment in the S&P 500 benchmark (also with dividends reinvested).

08

ABBV stock price prediction 2030

ABBV Stock Price Prediction 2030: Simulated Scenarios

Price today
$286
Base case, 2030
$415
1.4x over 4 years
Range, 2030
$212 to $810
10th to 90th percentile

CleaRank's simulation projects a price near $415 for ABBV by 2030 in the base case, from $286 today (1.4x over 4 years). The 10th-percentile path ends near $212. These are outcomes of a Monte Carlo simulation run on ABBV's historical return distribution, not price targets, and they assume no dividends are reinvested.

ABBV simulated price paths by year
Year 10th percentile Base case 90th percentile range base today
2027 $225 $314 $439
2028 $215 $344 $553
2029 $212 $378 $675
2030 $212 $415 $810
09

ABBV insider trading

ABBV insider trading

Bought
None
no open-market buys
Sold
$41.9M
7 open-market sales
Insiders filing
20
over the last 18 months
Average trade
$6.0M
buys and sales together

Month by month

Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26Nov '26

Net insider selling: No insider bought ABBV shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.

Insider transactions in ABBV
Date Insider Type Shares Value
Nov 12, 2026
Jeffrey Ryan Stewart
Officer
Grant 3.5K -
Nov 9, 2026
Jeffrey Ryan Stewart
Officer
Sell 40.6K $11.9M
Nov 9, 2026
Jeffrey Ryan Stewart
Officer
Option 40.6K $4.1M
Aug 14, 2026
Nicholas Donoghoe
Officer
Sell 32.7K $8.2M
Aug 14, 2026
Nicholas Donoghoe
Officer
Option 32.7K $2.6M
May 8, 2026
Roxanne Schuh Austin
Director
Grant 1.1K -
May 8, 2026
William H L Burnside
Director
Grant 1.1K -
May 8, 2026
Jennifer L Davis
Director
Grant 1.1K -
May 8, 2026
Thomas J Falk
Director
Grant 1.1K -
May 8, 2026
Thomas C Freyman
Director
Grant 1.1K -
10

ABBV stock forecast: questions people ask

ABBV Forecast: Frequently Asked Questions

What is the ABBV stock forecast?
The analysts' median 12-month price target is $317.00, which is 10.8% above the price of $286.20, with the lowest target at $237.00 and the highest at $350.00 across 29 analysts. The nearest level below the price is the 50-day simple moving average at $279.00. The nearest level above it is the 20-day exponential moving average at $288.54.
What is the ABBV price target?
The median 12-month analyst target is $317.00, with the lowest target at $237.00 and the highest at $350.00. The consensus rating is Buy, with 23 of 29 analysts rating the stock buy or strong buy. The price is 9.7% below the median target.
Is ABBV a buy or sell today?
Analysts rate the stock Buy, with 23 of 29 analysts rating it buy or strong buy, 5 at hold and 1 at sell. CleaRank rates it Buy with a score of 66 out of 100. The price is 2.58% above its 50-day average and 18.04% above its 200-day average, and both averages are rising in step with the trend.
How does AbbVie's valuation compare with peers?
The trailing P/E of 49.18 is a premium to the sector median of 31.9, which is 54.2% above it. The price-to-sales ratio of 7.73 is 127.2% above the sector median of 3.4. Valuation is the factor that pulls the CleaRank score down the most.
How has AbbVie performed in its recent earnings reports?
AbbVie beat the EPS estimate in all four of the most recent reports, the latest by 1.60% on October 30, 2026. The shares fell in the first session after three of those four reports, including a 2.05% drop after the October 30, 2026 report.
What does the dividend look like?
The trailing dividend yield is 2.42%, based on an annual dividend of $6.92 per share. At a price of $286.20, that yield is modest compared with the stock's 24.73% gain over the past year.
How has the stock performed over the past year?
The stock is up 24.73% over one year and 25.26% year to date. Its beta against the S&P 500 is 0.19, so its moves have been small relative to the broad market.

How these figures are computed, and where the data comes from: CleaRank methodology.

Disclaimer: CleaRank.com is a financial data and analytics provider, not a registered investment advisor, broker-dealer, or financial regulatory body. The stock analysis and AI-generated signals presented for ABBV are for educational and informational purposes only and do not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. Simulated scenarios and historical performance figures shown are hypothetical and hindsight-based. They do not represent actual trades made by CleaRank or its affiliates. Stock prices can be volatile and are subject to market, economic, and company-specific risks. Market data is provided "as-is" and may be delayed by up to a minute. We do not guarantee the accuracy, completeness, or timeliness of any data. You should never invest money you cannot afford to lose. Past performance does not guarantee future results. Consult a qualified financial advisor before making any investment decisions. Analysis generated on November 22, 2026.